Medical Newscast
Medical Newscast with http://www.mdnewscast.net

Medical Newscast

Medical Newscast

News for 20-Sep-16

Source: MedicineNet Diabetes General
Newest Diabetes Drugs Linked to Higher Pancreatitis Risk

Source: MedicineNet High Blood Pressure General
Beet Juice Lowers Blood Pressure

Source: MedicineNet High Blood Pressure General
Treating Kidneys With Radio Waves May Ease Tough-to-Control Hypertension

Source: MedicineNet Diabetes General
Artificial Pancreas Worked Overnight on Kids With Type 1 Diabetes

Source: MedicineNet High Blood Pressure General
Consider Weight When Choosing Blood Pressure Meds: Study

Source: MedicineNet Diabetes General
Too Much Sitting Could Court Diabetes, Study Finds

Source: MedicineNet High Blood Pressure General
Fainting Spells Often Tied to Too Many Meds at Once: Study

Source: MedicineNet Diabetes General
Countries With More Sugar in Food Supply Have More Diabetes

Source: MedicineNet High Blood Pressure General
benazepril and hydrochlorothiazide, Lotensin HCT

Source: MedicineNet High Blood Pressure General
Low Wages Linked to Raised Risk for High Blood Pressure

The Best Medical Newscast website

All the Medical Newscast information you need to know about is right here. Presented and researched by http://www.mdnewscast.net. We've searched the information super highway far and wide to provide you with the best Medical Newscast site on the internet today. The links below will assist you in your efforts to find the information that you are looking for about
Medical Newscast.

Medical Newscast

Medical Newscast
For information about Medical Newscasts look no further. We have links to great resources regarding all forms of medical internet broadcasting.
Medical Newscast

How do we know they're the best Medical Newscast websites available on the net today? Because we've spent months painstakingly researching the subject. We've visited every site about Medical Newscast we could find, and we've studied them to sort the good from the bad.

Look, we're good at getting ranked well in search engines. Medical Newscast might be our big interest, but we'll be the first to admit that out site doesn't come anywhere near the quality of the websites we're linking to. So what we suggest you do is follow one the links. You won't be disappointed. Thanks for visiting our webpage, and please come back again one day. Next time you visit you might find that we're the best Medical Newscast place online.

Drug Offers Hope to Cancer Patients

 by: ARA Content

(ARA) - A decade ago, research into angiogenesis-inhibiting compounds was still in a relative state of infancy. The principle itself was not new -- as far back as the early '70s, there was speculation that human cancer tumors could not grow beyond a few millimeters in diameter without obtaining their own blood supply. But opinion was still divided in the scientific community.

Angiogenesis itself is a natural and necessary physiological function, which refers to the process by which new blood vessels form and develop. In its pathological form, however, angiogenesis is also implicated in the progression of more than 20 different diseases, including cancer.

In order to grow, solid tumors need to be supplied by blood vessels that act as conduits for oxygen and nutrients. Once a vascular network has been generated around a tumor, cancerous cells can then invade the rest of the body, a process called metastasis. Angiogenesis inhibitors block the formation of new blood vessels, without which cancerous cells are starved and tumors cannot grow.

In recent years, the therapeutic potential of angiogenesis inhibitors has gained wide acceptance. Indeed, the scientific community now believes that more than 90 percent of all cancer cases are angiogenesis dependent. The industry spends nearly $4 billion annually in angiogenic research and more than 100 research organizations and companies are currently developing angiogenesis-blocking drugs.

Ęterna Laboratories Inc. is at the forefront of this effort. In fact, it is one of the very few biotechnology companies in the world with an angiogenesis-blocker in Phase lll clinical development. Its proprietary compound, Neovastat, is currently the subject of Phase III trials in lung and kidney cancer and a Phase ll trial in multiple myeloma, a form of blood cancer.

Neovastat possesses multiple mechanisms of action that counteract the angiogenic process. Among competing products, this makes it unique. It has also shown an excellent safety profile in clinical trials. Further advantages of Neovastat are that it is orally administered, which makes it convenient for patients who must receive treatment on a long-term basis, and it may be taken in association with standard therapies such as chemotherapy.

Angiogenesis blockers are not a cure for cancer. They are a form of treatment -- in the same way that insulin is a treatment for diabetes -- that should allow patients to lead a more normal life, without suffering from the often debilitating side-effects that some treatments can produce.

Ęterna's clinical trials strategy has targeted forms of cancer for which there is an urgent need for new therapies. Since 1996, Neovastat has been tested in more than 850 patients in North American and European countries. Currently, Neovastat is the subject of three clinical trials, targeting three forms of cancer. For multiple myeloma, the second most common form of blood cancer, the drug is in Phase II trials with 125 patients in the United States, Canada and Europe. This trial should be completed in early 2003. For progressive renal cell carcinoma, the drug is in Phase III trials with 302 patients in the United States, Canada and Europe, which should be completed in early 2003. For non-small cell lung cancer, Neovastat is in a Phase III trial sponsored by the National Cancer Institute with 760 patients in the United States and Canada. This trial should be completed in 2005.

Once the clinical trials are complete, health authorities in various countries can then assess these results and make decisions on approval.

About The Author

Courtesy of ARA Content, www.ARAcontent.com; e-mail: info@ARAcontent.com

EDITOR'S NOTE: For more information about current trials call (888) 349-3232. For additional information, contact Paul Burroughs, director of communications, (418) 652-8525, Ext. 406. Neovastat is being developed by Ęterna Laboratories of Quebec, Canada.

To learn more about anti-angiogenesis and Ęterna Laboratories, visit the Ęterna Web site at www.aeterna.com. For more information about the NCI's clinical trials, visit http://cancertrials.nci.nih.gov.

Google

http://www.medmeet.com/
Real Time Media On The Net | Medical Presentations | Go Meetings | Affordable Used Cars | Internet Meetings

Medical Meetings   Meetings On The Net   Fantasy Football Strategies